Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-04-12 Proxy Solicitation & In…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Circular to Shareholders and Notice of General Meeting
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled 'Circular to Shareholders and Notice of General Meeting' concerning the 'Acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca PLC'. It details the recommendation for shareholders to vote in favor of a resolution at the General Meeting, provides instructions on appointing a proxy (Form of Proxy), and references the Notice of General Meeting. This content strongly aligns with materials distributed to solicit shareholder votes and provide necessary information ahead of a general meeting, which falls under the definition of Proxy Solicitation & Information Statement (PSI). Although it mentions the proxy statement/prospectus filed with the SEC (Form F-4), the document itself is the UK Circular and Notice, making PSI the most accurate classification for this specific communication to UK shareholders regarding the vote.
2021-04-12 English
Circular and notice of general meeting
AGM Information Classification · 95% confidence The document is an RNS announcement dated April 12, 2021, regarding the 'Publication of Circular and notice of AstraZeneca General Meeting regarding the acquisition of Alexion'. It explicitly states that a Circular (which contains the notice of general meeting) has been published and provides a link to it. It also mentions that the Annual General Meeting (AGM) will take place on May 11, 2021, and encourages participation in an online shareholder engagement event related to the AGM and the acquisition. Since the document's primary function is to announce the publication of the Circular (which includes the notice for the General Meeting) and details about the upcoming AGM, it relates closely to shareholder meetings and associated documentation. The presence of the AGM date and the announcement of the Circular strongly points towards AGM-related materials. Given the options, AGM-R (AGM Information) is the most appropriate fit as it covers presentations and materials shared during the AGM, and this announcement directly relates to the upcoming AGM and the associated shareholder meeting for the acquisition approval. Although it announces a Circular, the context heavily involves the General Meeting itself.
2021-04-12 English
UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the DARE-19 Phase III trial results for Farxiga in COVID-19 patients. The document includes detailed clinical trial results, background on the drug, and company information. It is not an annual or quarterly report, nor is it a transcript, proxy, or governance document. The Form 6-K is a regulatory filing used by foreign companies to report material information to the SEC. Given the nature of the document as a Form 6-K and the detailed update it provides, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document length (9346 characters) and content confirm it is a full report rather than a brief announcement or certification.
2021-04-12 English
Update on Farxiga COVID-19 DARE-19 Phase III trial
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 1076V' and is dated '12 April 2021'. It announces high-level results from a Phase III clinical trial (DARE-19) for a drug (Farxiga) in treating COVID-19 patients. The structure, use of RNS identifiers, and the nature of the announcement (a material update on clinical trial results) strongly indicate this is a regulatory news service release from the London Stock Exchange (RNS). Since it is an announcement of clinical trial results, it fits best under the general Regulatory Filings category (RNS), as it is not a full Earnings Release (ER), Interim Report (IR), or a specific management/board change. It is a general regulatory disclosure.
2021-04-12 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a detailed circular to shareholders regarding the acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca PLC. It is filed pursuant to Rule 425 under the U.S. Securities Act of 1933, which is typically used for merger communications. The document includes a notice of a general meeting, proxy information, and detailed instructions for shareholders on voting and participation. It references a proxy statement/prospectus and registration statements filed with the SEC, which are typical in merger and acquisition transactions. The presence of terms like 'Circular to Shareholders', 'Notice of General Meeting', 'proxy statement', and the Rule 425 filing strongly indicate this is related to merger communications. Therefore, the document fits best under the category of Merger & Acquisition filings, specifically Rule 425 communications related to a takeover bid or merger proposal.
2021-04-12 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a communication filed pursuant to Rule 425 under the US Securities Act of 1933, related to AstraZeneca's acquisition of Alexion Pharmaceuticals. It announces the publication of a shareholder circular and notice of a general meeting regarding the acquisition transaction. The text references a proxy statement/prospectus filed with the SEC, a shareholder meeting to approve the transaction, and details about the transaction process. The document is not the circular itself but an announcement about the publication of the circular and the meeting. It is a regulatory announcement related to merger activity but does not contain the merger filing forms themselves or detailed merger documents. Given the Rule 425 filing nature and the announcement of the circular and meeting, this fits best under the category of Merger & Acquisition (MA) filings, which include merger communications such as Form 425. The document is substantive and not a mere report publication announcement or proxy solicitation material. Therefore, the classification is MA with high confidence.
2021-04-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.